Spring Bank Pharmaceuticals announced additional pre-clinical data from its second-generation STimulator of Interferon Genes, or STING, agonist program. Spring Bank will present the data in three poster presentations at the AACR special conference. Spring Bank is developing multiple second-generation STING agonist compounds that are designed to activate the innate and adaptive immune systems. Spring Bank believes that its STING agonists are best-in-class agents and are differentiated due to their potential to be administered either intravenously, or IV, or intratumorally, or IT, for potent and durable anti-tumor activity in multiple cancer models. Spring Bank’s STING agonists also have the potential to be used in combination with other therapeutic modalities to enhance efficacy. Subject to completion of IND-enabling studies, Spring Bank plans to initiate clinical trials for SB 11285 in 2019. SB 11285 could be the first IV administered STING agonist to enter clinical development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.